Krufton

Nilotinib, the active ingredient in Krufton, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It selectively targets the BCR‑ABL fusion protein, thereby inhibiting the proliferation of Philadelphia chromosome‑positive leukemic cells. The drug is employed in the management of chronic myeloid leukemia, particularly in adult patients who have demonstrated resistance or intolerance to prior therapy.

GNH USA supplies Krufton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Krufton (nilotinib) is used to treat Philadelphia chromosome‑positive chronic myeloid leukemia across disease phases. - Chronic phase CML: reduces disease progression and achieves cytogenetic response. - Accelerated phase CML: provides hematologic and cytogenetic improvement when other TKIs are unsuitable. - Blast phase CML: offers disease control in patients resistant to prior therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often transient. - Rash: maculopapular skin eruptions. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Hepatotoxicity: elevated liver transaminases. - Severe neutropenia: increased infection risk. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Vascular events: arterial occlusive disease.

Before initiating therapy, patients should be evaluated for cardiac and hepatic health. - Cardiac monitoring: baseline ECG and periodic QT assessment. - Blood count surveillance: regular CBC to detect neutropenia. - Liver function tests: monitor ALT/AST levels. - Avoid in known QT‑prolonging conditions: contraindicated in patients with congenital long QT syndrome. - Dose adjustment in hepatic impairment: reduce dose if moderate liver dysfunction is present. - Store at below 25°C: keep in the original pack, protect from moisture.

Nilotinib may interact with several concomitant medications. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can lower absorption if taken simultaneously. Moderate Interactions (Monitor Closely): - Proton pump inhibitors (e.g., omeprazole): may modestly affect bioavailability. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy. - Warfarin: potential alteration of INR, requiring closer coagulation monitoring.